“The nation’s scientific enterprise is being decimated.” That statement in an open letter “to the American people” signed by 1,800 members of the U.S. National Academies, is made concrete in a list of 709 NIH grants – and counting – that have been axed since President Donald Trump was inaugurated on Jan. 20.
“The nation’s scientific enterprise is being decimated.” That statement in an open letter “to the American people” signed by 1,800 members of the U.S. National Academies, is made concrete in a list of 709 NIH grants – and counting – that have been axed since President Donald Trump was inaugurated on Jan. 20. A grant tracker, based on information published by the Department of Health and Human Sciences, and self-reported terminations from scientists, includes 88 vaccine-related projects, 45 cancer research grants and 231 awards made for HIV research.
Shares of Chinese and South Korean med-tech companies continued to rise after the World Health Organization declared mpox a public health emergency of international concern Aug. 14 after recent outbreaks.
A vaccine based on messenger RNA (mRNA) technology against four surface proteins of the envelope and the inner membrane of the mpox virus (MPXV) demonstrated its efficacy in two animal models. Biontech SE scientists designed and tested two different combinations of antigens in mice and macaques for the two infective forms of the virus. One of them showed better results for its evaluation in clinical trials preventing the disease.
Biontech SE and the Coalition for Epidemic Preparedness Innovations (CEPI) have established a strategic partnership to advance mRNA-based vaccine candidates with the development of BNT-166 for the prevention of mpox (formerly monkeypox).
Blue Water Biotech Inc. has released preliminary preclinical data supporting the use of its norovirus shell and protrusion (S&P) virus-like particle (VLP) platform to develop a novel mpox vaccine candidate.
An ongoing outbreak of mpox, a viral disease of zoonotic origin, was confirmed in May 2022 and has affected many countries worldwide. The spread of the virus is due to human-to-human transmission, but it remains unclear whether the responsible mpox strain is adapting to a new host.
Just as the U.S. mpox public health emergency declaration is about to end, the FDA is releasing a draft guidance on developing drugs and biologics to treat infections caused by the virus.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Life Spine, Medcognetics, Miromatrix, Providence Medical Technology, Thermo Fisher Scientific.
Ascletis Pharma Inc. announces that the company has filed an IND application with the FDA for ASC-10, an oral antiviral drug candidate targeting viral polymerase of monkeypox virus.
